Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent Malignant Pleural Mesothelioma
NCT02497508Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in malignant pleural mesothelioma (MPM), sponsored by Netherlands Cancer Institute. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02497508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497508.